Symbols / ATHE $3.44 -3.71% Alterity Therapeutics Limited
ATHE Chart
About
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 65.00M |
| Enterprise Value | 38.78B | Income | -14.59M | Sales | 6.64M |
| Book/sh | 0.00 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -8.69 | PEG | — |
| P/S | 9.79 | P/B | 1003.69 | P/C | — |
| EV/EBITDA | -2209.39 | EV/Sales | 5842.93 | Quick Ratio | 21.68 |
| Current Ratio | 21.98 | Debt/Eq | 0.18 | LT Debt/Eq | — |
| EPS (ttm) | -0.58 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | 74.60% | Earnings | 2015-08-25 20:00 | ROA | -32.54% |
| ROE | -47.02% | ROIC | — | Gross Margin | 97.55% |
| Oper. Margin | -3.73% | Profit Margin | -219.85% | Shs Outstand | 18.13M |
| Shs Float | 8.31B | Short Float | 0.06% | Short Ratio | 0.98 |
| Short Interest | — | 52W High | 7.00 | 52W Low | 2.52 |
| Beta | 0.05 | Avg Volume | 11.82K | Volume | 1.42K |
| Target Price | $11.00 | Recom | None | Prev Close | $3.57 |
| Price | $3.44 | Change | -3.71% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | init | Canaccord Genuity | — → Speculative Buy | — |
| 2025-01-30 | main | Maxim Group | Buy → Buy | $12 |
| 2024-12-12 | init | Maxim Group | — → Buy | $8 |
| 2024-03-07 | reit | Benchmark | Speculative Buy → Speculative Buy | $4 |
| 2023-06-05 | main | Ladenburg Thalmann | Buy → Buy | $10 |
- FDA feedback moves Alterity's atrophy drug toward Phase 3 - Stock Titan Mon, 30 Mar 2026 11
- ATHE Should I Buy - Intellectia AI Fri, 27 Mar 2026 07
- Alterity Therapeutics (NASDAQ: ATHE) gets positive FDA feedback on ATH434 Phase 3 MSA program - Stock Titan Mon, 30 Mar 2026 10
- Meet the team who treats injured cowboys at the stock show - KUSA.com hu, 22 Jan 2026 08
- White Castle, Fort Worth Stock Show’s grand champion steer, sells for a record $550,000 - KERA News Mon, 09 Feb 2026 08
- [6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K - Stock Titan hu, 26 Mar 2026 15
- Where to Eat During the National Western Stock Show - 5280 hu, 08 Jan 2026 08
- What to expect at the 2026 Fort Worth Stock Show & Rodeo - nbcdfw.com Fri, 16 Jan 2026 08
- ATHE SEC Filings - Alterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 13 Mar 2026 17
- CEO to share late-stage trial lessons at Bell Potter healthcare summit - Stock Titan Mon, 09 Mar 2026 07
- Alterity Therapeutics (NASDAQ: ATHE) plans 150M service-linked options - Stock Titan hu, 19 Mar 2026 07
- Alterity Therapeutics (ATHE) offers unmarketable parcel sale option to small holders - Stock Titan Fri, 13 Mar 2026 07
- Experimental MSA drug ATH434 inches toward Phase 3 on stronger data - Stock Titan Fri, 30 Jan 2026 08
- MSA trial expert Daniel Claassen to guide Alterity's ATH434 Phase 3 - Stock Titan Wed, 04 Mar 2026 08
- Aiming for first MSA therapy, Alterity targets $2.4B opportunity - Stock Titan Wed, 21 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
12.33
-36.43%
|
19.40
+35.04%
|
14.37
-5.08%
|
15.14
|
| Research And Development |
|
14.40
-22.74%
|
18.64
+41.26%
|
13.20
-10.49%
|
14.75
|
| Selling General And Administration |
|
5.34
+15.55%
|
4.62
-6.65%
|
4.95
-9.26%
|
5.46
|
| General And Administrative Expense |
|
5.34
+15.55%
|
4.62
-6.65%
|
4.95
-9.26%
|
5.46
|
| Salaries And Wages |
|
2.03
+44.98%
|
1.40
-26.16%
|
1.89
-14.41%
|
2.21
|
| Other Gand A |
|
2.77
+8.52%
|
2.55
+12.32%
|
2.27
-9.62%
|
2.51
|
| Other Operating Expenses |
|
-2.12
-40484.36%
|
0.01
-80.81%
|
0.03
+106.03%
|
-0.45
|
| Total Expenses |
|
12.33
-36.43%
|
19.40
+35.04%
|
14.37
-5.08%
|
15.14
|
| Operating Income |
|
-12.33
+36.43%
|
-19.40
-35.04%
|
-14.37
+5.08%
|
-15.14
|
| EBITDA |
|
-12.19
+36.67%
|
-19.25
-34.97%
|
-14.27
+5.42%
|
-15.08
|
| Normalized EBITDA |
|
-12.13
+37.86%
|
-19.52
-28.39%
|
-15.20
+14.63%
|
-17.81
|
| Reconciled Depreciation |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| EBIT |
|
-12.33
+36.43%
|
-19.40
-35.04%
|
-14.37
+5.08%
|
-15.14
|
| Total Unusual Items |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Total Unusual Items Excluding Goodwill |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Net Income |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Pretax Income |
|
-12.08
+36.68%
|
-19.08
-39.23%
|
-13.70
-7.24%
|
-12.78
|
| Net Non Operating Interest Income Expense |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Net Interest Income |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Interest Income Non Operating |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Interest Income |
|
0.45
+66.27%
|
0.27
+1533.12%
|
0.02
+556.39%
|
0.00
|
| Other Income Expense |
|
-0.19
-440.36%
|
0.06
-91.30%
|
0.65
-72.44%
|
2.36
|
| Other Non Operating Income Expenses |
|
-0.13
+38.78%
|
-0.20
+28.22%
|
-0.29
+21.83%
|
-0.36
|
| Gain On Sale Of Security |
|
-0.07
-125.70%
|
0.26
-72.06%
|
0.93
-65.66%
|
2.72
|
| Tax Provision |
|
0.07
+47.66%
|
0.05
-55.88%
|
0.10
+49.21%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.02
-125.70%
|
0.08
-72.06%
|
0.28
-65.66%
|
0.82
|
| Net Income Including Noncontrolling Interests |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income From Continuing And Discontinued Operation |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Net Income Continuous Operations |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Normalized Income |
|
-12.10
+37.32%
|
-19.31
-33.51%
|
-14.46
+1.98%
|
-14.75
|
| Net Income Common Stockholders |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Diluted EPS |
|
-1.14
+63.46%
|
-3.12
-447.37%
|
-0.57
+82.08%
|
-3.18
|
| Basic EPS |
|
-1.14
+63.46%
|
-3.12
-447.37%
|
-0.57
+82.08%
|
-3.18
|
| Basic Average Shares |
|
10.66
+75.31%
|
6.08
-74.95%
|
24.28
+505.45%
|
4.01
|
| Diluted Average Shares |
|
10.66
+75.31%
|
6.08
-74.95%
|
24.28
+505.45%
|
4.01
|
| Diluted NI Availto Com Stockholders |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Depreciation Amortization Depletion Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation And Amortization In Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation Income Statement |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Insurance And Claims |
|
0.55
-18.75%
|
0.68
-6.31%
|
0.72
+10.02%
|
0.66
|
| Other Taxes |
|
-5.44
-35.32%
|
-4.02
-2.68%
|
-3.91
+16.17%
|
-4.67
|
| Rent And Landing Fees |
|
—
|
—
|
0.07
-13.48%
|
0.08
|
| Rent Expense Supplemental |
|
—
|
—
|
0.07
-13.48%
|
0.08
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
46.03
+139.42%
|
19.22
-29.63%
|
27.32
-33.96%
|
41.36
|
| Current Assets |
|
45.87
+140.96%
|
19.04
-29.62%
|
27.05
-34.26%
|
41.14
|
| Cash Cash Equivalents And Short Term Investments |
|
40.66
+221.69%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Cash And Cash Equivalents |
|
33.16
+162.35%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Other Short Term Investments |
|
7.50
|
0.00
|
—
|
—
|
| Receivables |
|
3.94
-2.57%
|
4.04
-53.36%
|
8.67
+83.39%
|
4.73
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
0.07
|
0.00
|
| Taxes Receivable |
|
3.94
-2.57%
|
4.04
-53.00%
|
8.60
+81.99%
|
4.73
|
| Accrued Interest Receivable |
|
0.00
-100.00%
|
0.00
-76.07%
|
0.00
+3544.44%
|
0.00
|
| Prepaid Assets |
|
1.23
-46.75%
|
2.32
-9.88%
|
2.57
+60.42%
|
1.60
|
| Other Current Assets |
|
0.04
+2.82%
|
0.04
+2.27%
|
0.04
+288.62%
|
0.01
|
| Total Non Current Assets |
|
0.16
-16.97%
|
0.19
-30.49%
|
0.27
+23.04%
|
0.22
|
| Net PPE |
|
0.16
-16.97%
|
0.19
-30.49%
|
0.27
+23.04%
|
0.22
|
| Gross PPE |
|
0.16
-16.97%
|
0.19
-74.36%
|
0.73
-0.58%
|
0.73
|
| Accumulated Depreciation |
|
—
|
-0.43
+6.03%
|
-0.46
+10.61%
|
-0.51
|
| Other Properties |
|
0.16
-16.97%
|
0.19
-74.36%
|
0.73
-0.58%
|
0.73
|
| Total Liabilities Net Minority Interest |
|
3.62
-33.22%
|
5.43
+20.44%
|
4.50
-23.57%
|
5.89
|
| Current Liabilities |
|
3.53
-34.22%
|
5.37
+22.63%
|
4.38
-24.71%
|
5.82
|
| Payables And Accrued Expenses |
|
2.59
-44.09%
|
4.64
+30.75%
|
3.55
-30.57%
|
5.11
|
| Payables |
|
0.57
-6.17%
|
0.61
-65.60%
|
1.78
-65.18%
|
5.11
|
| Accounts Payable |
|
0.54
-7.38%
|
0.58
-66.14%
|
1.72
-66.22%
|
5.08
|
| Other Payable |
|
0.02
+33.41%
|
0.01
-57.45%
|
0.03
-41.14%
|
0.06
|
| Current Accrued Expenses |
|
2.02
-49.86%
|
4.02
+127.67%
|
1.77
-25.09%
|
2.36
|
| Employee Benefits |
|
—
|
0.00
-100.00%
|
0.02
+41.81%
|
0.01
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.88
+65.05%
|
0.53
-27.22%
|
0.73
+11.11%
|
0.66
|
| Total Tax Payable |
|
0.02
+1.78%
|
0.02
-42.73%
|
0.03
+3.74%
|
0.03
|
| Current Debt And Capital Lease Obligation |
|
0.07
-37.54%
|
0.11
-0.04%
|
0.11
+85.97%
|
0.06
|
| Current Capital Lease Obligation |
|
0.07
-37.54%
|
0.11
-0.04%
|
0.11
+85.97%
|
0.06
|
| Other Current Liabilities |
|
0.00
-99.86%
|
0.10
|
—
|
-0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
0.09
+70.56%
|
0.05
-57.69%
|
0.12
+66.70%
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
0.09
+70.56%
|
0.05
-49.70%
|
0.10
+72.42%
|
0.06
|
| Long Term Capital Lease Obligation |
|
0.09
+70.56%
|
0.05
-49.70%
|
0.10
+72.42%
|
0.06
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
—
|
0.00
-100.00%
|
0.02
|
—
|
| Stockholders Equity |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Common Stock Equity |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Capital Stock |
|
262.95
+17.83%
|
223.15
+4.29%
|
213.97
+0.09%
|
213.79
|
| Common Stock |
|
262.95
+17.83%
|
223.15
+4.29%
|
213.97
+0.09%
|
213.79
|
| Share Issued |
|
9,127.37
+74.02%
|
5,245.12
+114.97%
|
2,439.90
+1.37%
|
2,406.87
|
| Ordinary Shares Number |
|
9,127.37
+74.02%
|
5,245.12
+114.97%
|
2,439.90
+1.37%
|
2,406.87
|
| Retained Earnings |
|
-225.89
-5.48%
|
-214.16
-9.75%
|
-195.13
-7.28%
|
-181.88
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
—
|
3.57
|
| Total Equity Gross Minority Interest |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Total Capitalization |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Working Capital |
|
42.34
+209.86%
|
13.66
-39.72%
|
22.67
-35.83%
|
35.32
|
| Invested Capital |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Total Debt |
|
0.16
-2.26%
|
0.16
-24.40%
|
0.21
+79.07%
|
0.12
|
| Capital Lease Obligations |
|
0.16
-2.26%
|
0.16
-24.40%
|
0.21
+79.07%
|
0.12
|
| Net Tangible Assets |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Tangible Book Value |
|
42.40
+207.31%
|
13.80
-39.52%
|
22.81
-35.68%
|
35.47
|
| Other Equity Interest |
|
5.34
+11.15%
|
4.81
+20.99%
|
3.97
+11.40%
|
3.57
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Cash Flow From Continuing Operating Activities |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Net Income From Continuing Operations |
|
-12.15
+36.48%
|
-19.12
-38.51%
|
-13.81
-7.47%
|
-12.85
|
| Depreciation Amortization Depletion |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Depreciation And Amortization |
|
0.14
-5.30%
|
0.15
+44.26%
|
0.10
+88.63%
|
0.05
|
| Other Non Cash Items |
|
0.45
|
—
|
—
|
0.00
|
| Stock Based Compensation |
|
0.98
+11.11%
|
0.88
-8.75%
|
0.97
-35.82%
|
1.51
|
| Asset Impairment Charge |
|
0.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Operating Gains Losses |
|
-0.26
+0.66%
|
-0.26
+71.54%
|
-0.92
+67.39%
|
-2.81
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.26
+0.66%
|
-0.26
+71.54%
|
-0.92
+67.39%
|
-2.81
|
| Change In Working Capital |
|
-0.61
-110.67%
|
5.75
+189.96%
|
-6.39
-462.49%
|
1.76
|
| Change In Receivables |
|
0.10
-97.75%
|
4.62
+217.35%
|
-3.94
-780.16%
|
-0.45
|
| Change In Payables And Accrued Expense |
|
-2.04
-285.48%
|
1.10
+170.62%
|
-1.56
-159.94%
|
2.60
|
| Change In Payable |
|
-2.04
-285.48%
|
1.10
+170.62%
|
-1.56
-159.94%
|
2.60
|
| Change In Other Working Capital |
|
0.35
+258.35%
|
-0.22
-377.06%
|
0.08
-35.97%
|
0.12
|
| Change In Other Current Assets |
|
1.08
+327.44%
|
0.25
+126.13%
|
-0.97
-87.57%
|
-0.52
|
| Change In Other Current Liabilities |
|
-0.10
-736.71%
|
-0.01
|
0.00
|
0.00
|
| Investing Cash Flow |
|
-7.50
-130973.05%
|
-0.01
+84.31%
|
-0.04
+59.10%
|
-0.09
|
| Cash Flow From Continuing Investing Activities |
|
-7.50
-130973.05%
|
-0.01
+84.31%
|
-0.04
+59.10%
|
-0.09
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Capital Expenditure |
|
—
|
-0.01
+21.73%
|
-0.01
+91.80%
|
-0.09
|
| Net Investment Purchase And Sale |
|
-7.50
|
0.00
|
0.00
|
—
|
| Purchase Of Investment |
|
-7.50
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
-0.03
|
—
|
| Financing Cash Flow |
|
39.67
+330.43%
|
9.22
+7312.17%
|
0.12
-99.24%
|
16.30
|
| Cash Flow From Continuing Financing Activities |
|
39.67
+330.43%
|
9.22
+7312.17%
|
0.12
-99.24%
|
16.30
|
| Net Issuance Payments Of Debt |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Repayment Of Debt |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Long Term Debt Payments |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Net Long Term Debt Issuance |
|
-0.13
-1125.62%
|
-0.01
+82.69%
|
-0.06
-73.62%
|
-0.03
|
| Net Common Stock Issuance |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Net Other Financing Charges |
|
-2.77
-202.19%
|
-0.92
-593.30%
|
-0.13
+84.18%
|
-0.84
|
| Changes In Cash |
|
20.72
+710.21%
|
-3.40
+82.98%
|
-19.95
-614.37%
|
3.88
|
| Effect Of Exchange Rate Changes |
|
-0.20
-176.19%
|
0.26
-71.54%
|
0.91
-67.48%
|
2.81
|
| Beginning Cash Position |
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
+23.80%
|
28.12
|
| End Cash Position |
|
33.16
+162.35%
|
12.64
-19.87%
|
15.77
-54.68%
|
34.81
|
| Free Cash Flow |
|
-11.45
+9.20%
|
-12.61
+37.08%
|
-20.04
-61.29%
|
-12.43
|
| Cash Flowsfromusedin Operating Activities Direct |
|
-11.45
+9.16%
|
-12.61
+37.08%
|
-20.04
-62.40%
|
-12.34
|
| Classesof Cash Payments |
|
-17.53
+18.29%
|
-21.45
-7.00%
|
-20.05
-18.49%
|
-16.92
|
| Classesof Cash Receiptsfrom Operating Activities |
|
5.63
-34.41%
|
8.58
|
—
|
4.58
|
| Common Stock Issuance |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Interest Paid Direct |
|
0.00
+100.00%
|
-0.01
-58.09%
|
-0.00
-99.78%
|
-0.00
|
| Interest Received Direct |
|
0.45
+65.86%
|
0.27
+1603.22%
|
0.02
+473.43%
|
0.00
|
| Issuance Of Capital Stock |
|
42.57
+319.64%
|
10.14
+3103.50%
|
0.32
-98.16%
|
17.18
|
| Other Cash Receiptsfrom Operating Activities |
|
—
|
—
|
—
|
0.45
|
| Paymentsto Suppliersfor Goodsand Services |
|
-17.46
+18.39%
|
-21.39
-7.27%
|
-19.94
-18.18%
|
-16.88
|
| Receiptsfrom Government Grants |
|
—
|
—
|
0.00
-100.00%
|
0.45
|
| Taxes Refund Paid Direct |
|
5.56
-34.77%
|
8.53
+8340.90%
|
-0.10
-102.53%
|
4.08
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|